ライフィクスアナリティカル Official site

Contact Us
  • COMPANY

We will further promote technological development and growth through a strategic partnership with IMA Life.

ライフィクスアナリティカル

ライフィクスアナリティカル

On November 18, 2024, RheaVita, a pioneer in controlled continuous freeze-drying technology for biopharmaceuticals, will announce a strategic partnership with IMA Life, one of the pharmaceutical divisions of the IMA Group, a global leader in advanced and sterile pharmaceutical processes and production solutions. This partnership includes a financial investment from IMA Life in RheaVita and ongoing support to expand the development and commercialization of RheaVita's cutting-edge technology in the global market.

Related Documents

Related Links

Regarding the partnership with IMALife

Related product information

  • RheaVita Corporation RheaLyo Mono System

    Reduction of time/cost in process development and improvement of quality in freeze-drying of biopharmaceuticals.

    【Other Features】 - Stable quality from preclinical trials to production during scale-up - Proven processes based on validated mechanical models and digital twin model-based design - Flexibility/production efficiency: short CIP/SIP times, flexible production volumes and capacities - Reduction of ecological footprint and operational costs (over 50%) *For more details, please refer to the PDF document or feel free to contact us.

Return to news list